By Ed Silverman | May 18, 2026
In a landmark decision that signals a deepening resolve among state regulators to rein in runaway pharmaceutical costs, the Maryland Prescription Drug Affordability Board (PDAB) has formally voted to impose an Upper Payment Limit (UPL) on Ozempic, the blockbuster GLP-1 receptor agonist manufactured by Novo Nordisk.
This move, finalized on May 18, 2026, marks the second time in just weeks that the Maryland panel has flexed its regulatory muscle to cap the costs of high-priced medications. By functioning effectively as a "utility commission for medicine," the state is charting a bold path that challenges the traditional pricing autonomy of the pharmaceutical industry, setting a precedent that could soon ripple across the United States.
The Core Decision: Capping the Cost of Innovation
The Maryland PDAB’s mandate is clear: to ensure that essential medications remain accessible to those who need them most. By establishing an upper payment limit for Ozempic—a drug widely used to manage type 2 diabetes—the board is moving to curtail the financial burden on state and local government health plans.
According to Andrew York, the executive director of the Maryland board, the cap is not arbitrary. The board utilized a benchmark derived from the "Maximum Fair Price" (MFP) framework established under the federal Medicare drug price negotiation program. By January 2027, the price for a 30-day supply of Ozempic will be capped at $274 for state-funded health programs. Board projections estimate that this single policy intervention will generate approximately $5.8 million in annual savings for Maryland’s public coffers.
This decision is not merely about accounting; it is about the broader philosophy of healthcare equity. As Ozempic and similar GLP-1 medications continue to dominate the market—not just for diabetes but for weight management—their soaring prices have placed an unsustainable strain on state budgets and employer-sponsored insurance pools alike.
A Chronology of Regulatory Assertiveness
The road to the Ozempic UPL was paved by months of meticulous data gathering and public hearings. The Maryland PDAB, established in 2019, spent its initial years building the legal and administrative infrastructure necessary to withstand the inevitable industry challenges.
- 2019: The Maryland General Assembly passes legislation creating the Prescription Drug Affordability Board, granting it the power to review the costs of certain high-priced drugs and, eventually, set upper payment limits.
- 2023-2024: The board refines its criteria for "affordability reviews," establishing thresholds based on list prices, price increases, and the impact on public health budgets.
- Early 2026: Following a series of public disclosures, the board signals that it is ready to move beyond analysis and toward active price regulation.
- May 2026: In rapid succession, the board takes action on two high-profile medications, culminating in the vote to cap the cost of Ozempic.
- January 2027: The effective date for the new $274 per month price cap for state and local government plans.
- 2028: The board is slated to expand its reach, targeting high-cost drugs across the broader commercial insurance market.
Supporting Data: Why Ozempic?
The selection of Ozempic was based on a rigorous assessment of its economic impact. The board’s analysis focused on several key variables:
- Volume and Spend: As a widely prescribed medication, the aggregate spend on Ozempic is significant. Even small reductions in the per-unit cost lead to millions in systemic savings.
- Lack of Competition: While other GLP-1s exist, the market is highly concentrated, allowing manufacturers to maintain high prices with limited downward pressure from generic alternatives.
- The Medicare Benchmark: By aligning with federal Medicare pricing data, Maryland is effectively "importing" a level of federal scrutiny to the state level, providing a robust legal defense for their pricing caps.
The $5.8 million in projected savings is just the tip of the iceberg. As the board gathers more longitudinal data on the use of Ozempic in Maryland, officials expect to refine these models, potentially identifying further opportunities for cost-containment.
Official Responses and Industry Pushback
Predictably, the pharmaceutical industry has met the Maryland PDAB’s actions with intense skepticism and legal posturing. Pharmaceutical Research and Manufacturers of America (PhRMA) and other industry advocacy groups have long argued that such caps stifle innovation.
"When you cap prices, you cap the future of medicine," one industry lobbyist noted anonymously. The argument is that high profit margins on successful drugs like Ozempic are necessary to fund the multi-billion-dollar R&D efforts required to bring the next generation of therapies to market.
Conversely, patient advocacy groups and state officials have lauded the move. "For too long, patients have had to choose between their health and their rent," said a representative from a Maryland-based healthcare equity group. "The board is finally treating medicine as a public good rather than a luxury commodity."
The Maryland PDAB has maintained that its process is transparent, data-driven, and legally sound. Andrew York has emphasized that the board provides a "due process" period where manufacturers can present evidence regarding their pricing, ensuring that the board’s decisions are based on the most accurate economic data available.
Implications for the Future: The 2028 Horizon
The most significant takeaway from the May 2026 decision is the roadmap for 2028. Currently, the board’s power to set payment limits is largely restricted to state and local government health plans. However, the legislation governing the PDAB envisions an expansion into the commercial market.
If Maryland successfully navigates the legal challenges that are certain to arise—likely involving claims of federal preemption and "takings" clauses—the state could become the blueprint for a nationwide movement. Other states with similar boards, such as Colorado and Washington, are watching Maryland’s progress with intense interest.
What This Means for Marylanders
For the average Maryland resident, the 2026 decision offers a glimpse of a future where drug prices are moderated by state oversight. By 2028, if the commercial market expansion succeeds, those with private insurance could see a stabilization—or even a reduction—in the out-of-pocket costs associated with chronic disease medications.
The Constitutional and Legal Landscape
The industry’s primary line of defense will be the courts. The "dormant Commerce Clause" and the potential for federal law (like the Inflation Reduction Act) to preempt state-level action will be the primary battlegrounds. If the Maryland PDAB wins these legal skirmishes, it will fundamentally alter the power dynamic between drug manufacturers and the states, effectively ending the era of unfettered price setting for high-demand medications.
Conclusion: A New Era of State-Level Regulation
The decision to cap the price of Ozempic is a watershed moment in American healthcare. By moving from analysis to active price enforcement, the Maryland Prescription Drug Affordability Board has transitioned from a watchdog into a regulator with real-world impact.
As the state prepares for the 2027 implementation and the 2028 expansion, all eyes will be on Maryland. If the board can demonstrate that it can lower costs without triggering the supply chain disruptions or innovation droughts warned of by industry lobbyists, it will provide the political cover needed for other states to follow suit.
For now, the message from Annapolis is clear: the status quo of pharmaceutical pricing is no longer sustainable. Whether through federal negotiation or state-level price caps, the era of unchecked list prices for essential medications is reaching a turning point. Maryland has chosen to lead that charge, and the pharmaceutical industry—and patients across the country—will be feeling the consequences for years to come.
